Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.
Τίτλος | Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Kanti, V., Messenger A., Dobos G., Reygagne P., Finner A., Blumeyer A., Trakatelli M., Tosti A., del Marmol V., Piraccini B. M., Nast A., & Blume-Peytavi U. |
Journal | J Eur Acad Dermatol Venereol |
Volume | 32 |
Issue | 1 |
Pagination | 11-22 |
Date Published | 2018 Jan |
ISSN | 1468-3083 |
Λέξεις κλειδιά | 5-alpha Reductase Inhibitors, Alopecia, Drug Therapy, Combination, Dutasteride, Evidence-Based Medicine, Female, Finasteride, Hair, Humans, Low-Level Light Therapy, Male, Minoxidil, Outcome Assessment, Health Care, Platelet-Rich Plasma, Practice Guidelines as Topic, Vasodilator Agents |
Abstract | Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. |
DOI | 10.1111/jdv.14624 |
Alternate Journal | J Eur Acad Dermatol Venereol |
PubMed ID | 29178529 |